MicroRNA-26a inhibits proliferation and metastasis of human hepatocellular carcinoma by regulating DNMT3B-MEG3 axis

Oncology Reports

Volumn 37, Issue 6, 2017, Pages 3527-3535

  Li, Yarui ^a   Ren, Mudan ^a   Zhao, Yan ^a   Lu, Xinlan ^a   Wang, Mengyao ^a   Hu, Junbi ^a   Lu, Guifang ^a   He, Shuixiang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

DNMT3B; Hepatocellular carcinoma; MEG3; MiR 26a

Indexed keywords

DNA METHYLTRANSFERASE 3B; LONG UNTRANSLATED RNA; MICRORNA 26A; DNA (CYTOSINE 5) METHYLTRANSFERASE; MEG3 NON-CODING RNA, HUMAN; MICRORNA; MIRN26A MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; METASTASIS INHIBITION; MIDDLE AGED; PRIORITY JOURNAL; TUMOR VOLUME; UPREGULATION; AGED; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METASTASIS; PATHOLOGY; SIGNAL TRANSDUCTION;

AGED; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; RNA, LONG NONCODING; SIGNAL TRANSDUCTION;

EID: 85019580031     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2017.5579     Document Type: Article

References (44)

1. Bellissimo F, Pinzone MR, Cacopardo B and Nunnari G: Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol 21: 12003-12021, 2015.
2. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, et al: Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28: 3994-4005, 2010.
3. Crissien AM and Frenette C: Current management of hepatocellular carcinoma. Gastroenterol Hepatol (NY) 10: 3994-4005, 2014.
4. Balogh J, Victor D III, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM and Monsour HP Jr: Hepatocellular carcinoma: A review. J Hepatocell Carcinoma 3: 41-53, 2016.
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
6. Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491, 2009.
7. Zhao ZC, Zheng SS, Wan YL, Jia CK and Xie HY: The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: The imbalance activation of signaling pathways. Hepatobiliary Pancreat Dis Int 2: 529-536, 2003.
8. Kawaji H, Severin J, Lizio M, Forrest AR, van Nimwegen E, Rehli M, Schroder K, Irvine K, Suzuki H, Carninci P, et al: Update of the FANTOM web resource: From mammalian transcriptional landscape to its dynamic regulation. Nucleic Acids Res 39 (Database): D856-D860, 2011.
9. Amorim M, Salta S, Henrique R and Jerónimo C: Decoding the usefulness of non-coding RNAs as breast cancer markers. J Transl Med 14: 265, 2016.
10. Beermann J, Piccoli MT, Viereck J and Thum T: Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches. Physiol Rev 96: 1297-1325, 2016.
11. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.
12. Arora A, Singh S, Bhatt AN, Pandey S, Sandhir R and Dwarakanath BS: Interplay between metabolism and oncogenic process: Role of microRNAs. Transl Oncogenomics 7: 11-27, 2015.
13. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
14. Yu X, Li Z, Yu J, Chan MT and Wu WK: MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif 48: 503-510, 2015.
15. Jansson MD and Lund AH: MicroRNA and cancer. Mol Oncol 6: 590-610, 2012.
16. Wen Y, Han J, Chen J, Dong J, Xia Y, Liu J, Jiang Y, Dai J, Lu J, Jin G, et al: Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer 137: 1679-1690, 2015.
17. Hu S, Tao R, Wang S, Wang C, Zhao X, Zhao H, Li L, Zhu S, He Y, Jiang X, et al: MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1. Tumour Biol 36: 5467-5472, 2015.
18. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 61: 278-289, 2012.
19. Zhang JP, Zeng C, Xu L, Gong J, Fang JH and Zhuang SM: MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene 33: 4069-4076, 2014.
20. Lai YY, Shen F, Cai WS, Chen JW, Feng JH, Cao J, Xiao HQ, Zhu GH and Xu B: MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma. Tumour Biol 37: 14165-14171, 2016.
21. Xue D, Zhou C, Lu H, Xu R, Xu X and He X: LncRNA GAS5 inhibits proliferation and progression of prostate cancer by targeting miR-103 through AKT/mTOR signaling pathway. Tumour Biol: Oct 14, 2016 (Epub Epub ahead of print).
22. Yim GW, Kim HJ, Kim LK, Kim SW, Kim S, Nam EJ and Kim YT: Long non-coding RNA HOXA11 antisense promotes cell proliferation and invasion and predicts patient prognosis in serous ovarian cancer. Cancer Res Treat: Oct 11, 2016 (Epub Epub ahead of print).
23. Wang J, Ye C, Xiong H, Shen Y, Lu Y, Zhou J and Wang L: Dysregulation of long non-coding RNA in breast cancer: An overview of mechanism and clinical implication. Oncotarget 8: 5508-5522, 2016.
24. Liu YR, Tang RX, Huang WT, Ren FH, He RQ, Yang LH, Luo DZ, Dang YW and Chen G: Long noncoding RNAs in hepatocellular carcinoma: Novel insights into their mechanism. World J Hepatol 7: 2781-2791, 2015.
25. Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y and Guo J: Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep 4: 6088, 2014.
26. Hu L, Ye H, Huang G, Luo F, Liu Y, Liu Y, Yang X, Shen J, Liu Q and Zhang J: Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tumour Biol 37: 2691-2702, 2016.
27. Deng J, He M, Chen L, Chen C, Zheng J and Cai Z: The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival. PLoS One 8: E76450, 2013.
28. Gao J, Li L, Wu M, Liu M, Xie X, Guo J, Tang H and Xie X: MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One 8: E65138, 2013.
29. Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y, Xu X, Wu J, Li S, Mao Q, et al: MiR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett 587: 2467-2473, 2013.
30. Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu YX, Liu JF and He ZM: MiR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One 8: E72662, 2013.
31. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM and Patel T: MicroRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 30: 4750-4756, 2011.
32. Guo P, Lan J, Ge J, Nie Q, Guo L, Qiu Y and Mao Q: MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. Exp Cell Res 320: 200-208, 2014.
33. Shen W, Song M, Liu J, Qiu G, Li T, Hu Y and Liu H: MiR-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS One 9: E86871, 2014.
34. Liu B, Wu X, Liu B, Wang C, Liu Y, Zhou Q and Xu K: MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta 1822: 1692-1704, 2012.
35. Zhao S, Ye X, Xiao L, Lian X, Feng Y, Li F and Li L: MiR-26a inhibits prostate cancer progression by repression of Wnt5a. Tumour Biol 35: 9725-9733, 2014.
36. Guo K, Zheng S, Xu Y, Xu A, Chen B and Wen Y: Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1. Tumour Biol 37: 12843-12854, 2016.
37. Melo SA and Esteller M: Dysregulation of microRNAs in cancer: Playing with fire. FEBS Lett 585: 2087-2099, 2011.
38. Sandhu R, Rivenbark AG and Coleman WB: Loss of post-transcriptional regulation of DNMT3b by microRNAs: A possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines. Int J Oncol 41: 721-732, 2012.
39. Nishida N, Nishimura T, Nakai T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, et al: Genomewide profiling of DNA methylation and tumor progression in human hepatocellular carcinoma. Dig Dis 32: 658-663, 2014.
40. Chen WC, Chen MF and Lin PY: Significance of DNMT3b in oral cancer. PLoS One 9: E89956, 2014.
41. Liu Z, Wang L, Wang LE, Sturgis EM and Wei Q: Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: A case-control study. Cancer Lett 268: 158-165, 2008.
42. Fan H, Chen L, Zhang F, Quan Y, Su X, Qiu X, Zhao Z, Kong KL, Dong S, Song Y, et al: MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma. Oncogene 31: 2298-2308, 2012.
43. Zhao J, Dahle D, Zhou Y, Zhang X and Klibanski A: Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab 90: 2179-2186, 2005.
44. Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, Cheunsuchon P, Louis DN and Klibanski A: Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 70: 2350-2358, 2010.